New CAR t therapy targets BAFFR to fight Hard-to-Treat leukemia
NCT ID NCT04690595
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This early-phase study tests a new type of CAR T cell therapy that targets a protein called BAFFR on leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The main goal is to check safety and side effects, while also seeing if the therapy can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.